Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery

Oh-Joon Kwon; Eunah Kang; Sungwan Kim; Chae-Ok Yun

doi:10.1016/j.jconrel.2011.06.014

journal article Oct 01, 2011

Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery

Oh-Joon Kwon Eunah Kang Sungwan Kim Chae-Ok Yun

Journal of Controlled Release Vol. 155 No. 2 pp. 317-325 · Elsevier BV

View at Publisher Save 10.1016/j.jconrel.2011.06.014

Topics

No keywords indexed for this article. Browse by subject →

References

29

[1]

McConnell "Biology of adenovirus and its use as a vector for gene therapy" Hum Gene Ther (2004) 10.1089/hum.2004.15.1022

[2]

Kanerva "Modified adenoviruses for cancer gene therapy" Int. J. Cancer (2004) 10.1002/ijc.20129

[3]

St George "Gene therapy progress and prospects: adenoviral vectors" Gene Ther. (2003) 10.1038/sj.gt.3302071

[4]

Kim "Evaluation of E1B gene-attenuated replicating adenoviruses for cancer gene therapy" Cancer Gene Ther. (2002) 10.1038/sj.cgt.7700494

[5]

Alemany "Replicative adenoviruses for cancer therapy" Nat. Biotechnol. (2000) 10.1038/77283

[6]

Choi "Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect" Gene Ther. (2006) 10.1038/sj.gt.3302759

[7]

Kim "Ad-mTERT-delta19, a conditional replication-competent adenovirus driven by the human telomerase promoter, selectively replicates in and elicits cytopathic effect in a cancer cell-specific manner" Hum. Gene Ther. (2003) 10.1089/104303403769211637

[8]

Kirn "Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer" Oncogene (2000) 10.1038/sj.onc.1204094

[9]

Kirn "Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?" Gene Ther. (2001) 10.1038/sj.gt.3301377

[10]

Kwon "A hypoxia- and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas" Clin. Cancer Res. (2010) 10.1158/1078-0432.ccr-10-0664

[11]

Green "Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus" Gene Ther. (2004) 10.1038/sj.gt.3302295

[12]

Stoff-Khalili "Employment of liver tissue slice analysis to assay hepatotoxicity linked to replicative and nonreplicative adenoviral agents" Cancer Gene Ther. (2006) 10.1038/sj.cgt.7700934

[13]

Yen "Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type" Cancer Gene Ther. (2000) 10.1038/sj.cgt.7700138

[14]

Sarkioja "Changing the adenovirus fiber for retaining gene delivery efficacy in the presence of neutralizing antibodies" Gene Ther. (2008) 10.1038/gt.2008.56

[15]

Wortmann "Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies" Mol. Ther. (2008) 10.1038/sj.mt.6300306

[16]

Yun "Coxsackie and adenovirus receptor binding ablation reduces adenovirus liver tropism and toxicity" Hum. Gene Ther. (2005) 10.1089/hum.2005.16.248

[17]

Park "Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction" J. Control Release (2010) 10.1016/j.jconrel.2009.11.001

[18]

Kim "The effect of surface modification of adenovirus with an arginine-grafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy" Biomaterials (2010) 10.1016/j.biomaterials.2009.11.043

[19]

Jung "Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells" J. Control Release (2007) 10.1016/j.jconrel.2007.08.002

[20]

Kim "Active targeting and safety profile of PEG-modified adenovirus conjugated with herceptin" Biomaterials (2011) 10.1016/j.biomaterials.2010.10.031

[21]

Park "Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy" J. Control Release (2010) 10.1016/j.jconrel.2010.06.027

[22]

Park "Enhanced delivery of adenovirus, using proteoliposomes containing wildtype or V156K apolipoprotein A-I and dimyristoylphosphatidylcholine" Hum. Gene Ther. (2010) 10.1089/hum.2008.207

[23]

Yang "Suppression of ovarian cancer growth via systemic administration with liposome-encapsulated adenovirus-encoding endostatin" Cancer Gene Ther. (2010) 10.1038/cgt.2009.47

[24]

Yotnda "Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses" Mol. Ther. (2002) 10.1006/mthe.2002.0545

[25]

Merritt "Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth" J. Natl Cancer Inst. (2008) 10.1093/jnci/djn024

[26]

Shi "Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model" Mol. Cancer Ther. (2002)

[27]

Takahashi "Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy" Adv. Drug Deliv. Rev. (2009) 10.1016/j.addr.2009.04.006

[28]

Li "Gene therapy progress and prospects: non-viral gene therapy by systemic delivery" Gene Ther. (2006) 10.1038/sj.gt.3302838

[29]

Shayakhmetov "Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity" J. Virol. (2005) 10.1128/jvi.79.12.7478-7491.2005

Cited By

34

Dual tumor targeting with pH-sensitive and bioreducible polymer-complexed oncolytic adenovirus

Chang Yoon Moon, Joung-Woo Choi · 2015

Biomaterials

Metrics

34

Citations

29

References

Details

Published: Oct 01, 2011
Vol/Issue: 155(2)
Pages: 317-325
License: View

Authors

O

Oh-Joon Kwon

1 Department of Urology, University of Washington, Seattle, Washington, USA

Department of Bioengineering, College of Engineering, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea; GeneMedicine Co., Ltd., 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea; Institute of Nano Science and Technology, 222 Wangsimni-ro, Seongdong-gu, Seoul 04763, Korea

Cite This Article

Oh-Joon Kwon, Eunah Kang, Sungwan Kim, et al. (2011). Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery. Journal of Controlled Release, 155(2), 317-325. https://doi.org/10.1016/j.jconrel.2011.06.014

Viral genome DNA/lipoplexes elicit in situ oncolytic viral replication and potent antitumor efficacy via systemic delivery

You May Also Like